Target-owned brand of frosted sugar cookies recalled due to possible contamination with wood pieces
Frosted sugar cookies sold at Target stores across the United States have been recalled because they may contain pieces of wood.
The U.S. Food and Drug Administration issued a recall for 803 cases of Favorite Day Bakery frosted sugar cookies sold at Target stores in 20 states and Washington, D.C. Favorite Day is a private label brand sold at Target.
The voluntary recall was initiated on July 22, 2025, by Give and Go Prepared Foods Corp in Etobicoke, Canada, which prepared the affected bakery items. As of Aug. 13, Target does not have the recall listed on its website.
How can I identify which specific cookies are recalled?
The affected Favorite Day Bakery frosted sugar cookies are the 10-count packages (Net wt. 13.5 oz.) with lot number 25195 and UPC code 85239-41250 3.
'Best By Date can vary as they are applied by retailer when removed from freezer,' the FDA indicates in the recall.
Has anyone gotten sick from the cookies?
No illnesses have been reported yet. However, the FDA classified the recall as Class II, which means eating the contaminated cookies 'may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.'
Where are the Target stores that sold the affected cookies?
The FDA says the affected cookies were distributed to Target stores in the following states and D.C.:
Connecticut
Delaware
Illinois
Indiana
Kentucky
Maine
Maryland
Massachusetts
Michigan
Missouri
New Hampshire
New Jersey
New York
North Carolina
Ohio
Pennsylvania
Rhode Island
Tennessee
Vermont
Virginia
Washington, D.C.
I bought the cookies that were recalled. What should I do?
Customers who purchased the affected frosted sugar cookies can get a full refund by bringing them to their nearest Target store or by calling Target guest relations at 1-800-440-0680.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
8 minutes ago
- Wall Street Journal
Dow Industrials Hit First Intraday High of 2025, Powered by UnitedHealth Shares
A major rally in UnitedHealth UNH 11.98%increase; green up pointing triangle Group stock propelled the Dow Jones Industrial Average to its first intraday record of 2025. UnitedHealth, the Dow's biggest laggard since early April, jumped 12% on Friday after a filing showed that Warren Buffett's Berkshire Hathaway BRK.B -0.42%decrease; red down pointing triangle took a roughly $1.6 billion position in the healthcare company during the second quarter. UnitedHealth stock remains down 40% for the year.
Associated Press
8 minutes ago
- Associated Press
Second Heart Assist's Whisper Device Poised to Advance AHA CKM Goals with Breakthrough Heart–Kidney Support
Proven kidney perfusion, heart unloading, and low hemolysis in testing, Whisper sets a new standard in integrated care for heart failure and kidney disease. 'The industry has been forced to choose between protecting the heart or the kidney. Whisper proves you can, and must, do both'— Jeff Donofrio, CEO- Second Heart Assist SALT LAKE CITY, CA, UNITED STATES, August 15, 2025 / / -- Second Heart Assist, Inc. is introducing its Whisper percutaneous mechanical circulatory support device as a potential new force in the fight against cardiovascular–kidney–metabolic (CKM) disease. Whisper is designed to enhance kidney perfusion while unloading the heart, supported by low hemolysis results in FDA-requested bench testing. The American Heart Association (AHA) has declared CKM syndrome a public health emergency, with only 10% of U.S. adults meeting 'excellent' CKM health standards. As the AHA expands its CKM initiative to 15 regions and 150 care sites, it is calling for earlier screening and integrated treatment that unites cardiology, nephrology, and metabolic care. Whisper's dual-organ approach was built to align with that vision. Performance that benefits both heart and kidney Many older-generation devices require extremely high rotational speeds to increase kidney flow, which can also raise red blood cell damage (hemolysis). Whisper is engineered for low-RPM performance and placed in the descending aorta just above the renal arteries. This position directs blood where the kidneys need it most while easing the heart's workload. 'The industry has been forced to choose between protecting the heart or the kidney. Whisper proves you can, and must, do both,' said Jeff Donofrio, CEO of Second Heart Assist. 'We have seen it in our international results and in our hemolysis data. Our focus is on delivering solutions that are fast to deploy, safe for patients, and effective where it matters most.' Company-reported OUS results • 28 patients treated outside the United States • No device-related adverse events • Average hospital stay of 48 hours • Zero readmissions during the initial follow-up period • Average deployment and initiation of treatment in under 2 minutes Hemolysis advantage In an FDA-requested in vitro study, Whisper showed approximately 50% less mechanical hemolysis than a comparator device (Impella) under identical conditions, operating at about 10,000 RPM versus more than 44,000 RPM required by the comparator to match flow. Expert perspectives Leslie W. Miller, MD, Chief Medical Officer, Second Heart Assist 'The CKM initiative will bring needed attention to the important dynamic interaction between the heart and kidney as heart failure triggers adverse responses in the kidneys that secondarily worsens kidney function and patients with intrinsic kidney impairment have a high incidence of secondary cardiac disease. The positioning of the SHA device provides simultaneous benefit to both the heart and kidneys by unloading the heart to increase cardiac output, and significantly increasing blood flow to the kidney to reverse the consequences of heart failure and stimulate the recovery of the function of both organs. Rob Coronado, MD, Advisor, Second Heart Assist 'For patients with vulnerable kidneys, every moment of optimized perfusion matters. Whisper reflects the priorities of CKM care. It supports kidney health, protect the heart, and make the therapy simple, safe, and fast to deliver.' Why this matters Heart failure readmissions remain among the most frequent and costly events in U.S. healthcare and are often linked to kidney decline. The AHA's CKM initiative emphasizes strategies that protect both organs to reduce complications, improve patient outcomes, and lower costs. Whisper's engineering and early results position it as a powerful candidate for this integrated approach. Next steps Second Heart Assist is preparing to launch its U.S. Early Feasibility Study, building on OUS experience and published bench data, with the goal of helping health systems deliver on AHA CKM objectives in real-world care. About Second Heart Assist Second Heart Assist develops percutaneous and implantable circulatory support systems intended to improve hemodynamics while addressing kidney-relevant flow needs. The company's U.S. patent portfolio includes U.S. Patent No. 11,602,627 and related international applications covering stent-cage pump configurations and renal-adjacent positioning concepts. Adam Steelwater Innovative Tech Capital Network email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Yahoo
an hour ago
- Yahoo
New emergency shelter to be built in central industrial area of Saskatoon
The City of Saskatoon has announced the location for an enhanced emergency shelter will be on 31st Street E., just off Idylwyld Drive. The site is currently a parking lot for Saskatchewan Polytechnic, which is relocating its campus to Innovation Place. The shelter will have about 60 beds and operate 24 hours a day, seven days a week, the city said in a news release. Clients will receive three meals a day, case planning and supports. A timeline for construction and an opening date have not been set yet. Neighbourhood information sessions are being planned for next month. The permanent location will replace the temporary shelter that opened in April 2025 on Pacific Avenue, in the city's downtown, which is only supposed to be open for 18 months. The number of homeless people in Saskatoon has been increasing. A point-in-time count on Oct. 8, 2024, identified 1,499 people experiencing homelessness, nearly three times higher than the previous count in 2022, which identified 550. The city is working on developing a Saskatoon Homelessness Action Plan, which passed the committee stage last month and is expected to be considered for approval this fall. The provincial government will lead the design and construction of the new facility on 31st Street E. and fund ongoing operations. The shelter will be operated by The Mustard Seed, a Christian non-profit organization.
